273 related articles for article (PubMed ID: 10515895)
21. Graft purging in autologous bone marrow transplantation: a promise not quite fulfilled.
Alvarnas JC; Forman SJ
Oncology (Williston Park); 2004 Jun; 18(7):867-76; discussion 876-8, 881, 884. PubMed ID: 15255171
[TBL] [Abstract][Full Text] [Related]
22. The effect of DNAse on the detection of residual malignant cells by polymerase chain reaction after immunologic purging of autologous bone marrow grafts.
Vervoordeldonk SF; Merle PA; Steenbergen EJ; van Leeuwen EF; von dem Borne AE; Slaper-Cortenbach IC
Prog Clin Biol Res; 1994; 389():601-9. PubMed ID: 7700926
[No Abstract] [Full Text] [Related]
23. Lack of t(14;18) polymerase chain reaction-positive cells in highly purified CD34+ cells and their CD19 subsets in patients with follicular lymphoma.
Voso MT; Hohaus S; Moos M; Haas R
Blood; 1997 May; 89(10):3763-8. PubMed ID: 9160682
[TBL] [Abstract][Full Text] [Related]
24. In multiple myeloma, circulating hyperdiploid B cells have clonotypic immunoglobulin heavy chain rearrangements and may mediate spread of disease.
Pilarski LM; Giannakopoulos NV; Szczepek AJ; Masellis AM; Mant MJ; Belch AR
Clin Cancer Res; 2000 Feb; 6(2):585-96. PubMed ID: 10690543
[TBL] [Abstract][Full Text] [Related]
25. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients.
Siena S; Bregni M; Brando B; Belli N; Ravagnani F; Gandola L; Stern AC; Lansdorp PM; Bonadonna G; Gianni AM
Blood; 1991 Jan; 77(2):400-9. PubMed ID: 1702334
[TBL] [Abstract][Full Text] [Related]
26. Innovative two-step negative selection of granulocyte colony-stimulating factor-mobilized circulating progenitor cells: adequacy for autologous and allogeneic transplantation.
Rambaldi A; Borleri G; Dotti G; Bellavita P; Amaru R; Biondi A; Barbui T
Blood; 1998 Mar; 91(6):2189-96. PubMed ID: 9490708
[TBL] [Abstract][Full Text] [Related]
27. Maturational regulation of globotriaosylceramide, the Shiga-like toxin 1 receptor, in cultured human gut epithelial cells.
Jacewicz MS; Acheson DW; Mobassaleh M; Donohue-Rolfe A; Balasubramanian KA; Keusch GT
J Clin Invest; 1995 Sep; 96(3):1328-35. PubMed ID: 7657808
[TBL] [Abstract][Full Text] [Related]
28. Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma.
Schiller G; Vescio R; Freytes C; Spitzer G; Sahebi F; Lee M; Wu CH; Cao J; Lee JC; Hong CH
Blood; 1995 Jul; 86(1):390-7. PubMed ID: 7540888
[TBL] [Abstract][Full Text] [Related]
29. Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell function.
Craiu A; Saito Y; Limon A; Eppich HM; Olson DP; Rodrigues N; Adams GB; Dombkowski D; Richardson P; Schlossman R; Choi PS; Grogins J; O'Connor PG; Cohen K; Attar EC; Freshman J; Rich R; Mangano JA; Gribben JG; Anderson KC; Scadden DT
Blood; 2005 Mar; 105(5):2235-8. PubMed ID: 15292069
[TBL] [Abstract][Full Text] [Related]
30. Effect of Ethiofos on cytotoxicity of pharmacological purging protocols used for autologous marrow grafts in acute lymphoblastic leukemia.
Skala JP; Rogers PC; Chan KW; Rodriguez WC
Prog Clin Biol Res; 1992; 377():57-62. PubMed ID: 1332075
[No Abstract] [Full Text] [Related]
31. Molecular detection of tumor contamination in peripheral blood stem cell harvests.
Craig JI; Langlands K; Parker AC; Anthony RS
Exp Hematol; 1994 Aug; 22(9):898-902. PubMed ID: 7914873
[TBL] [Abstract][Full Text] [Related]
32. Ex vivo treatment of myeloma cells by 4-HC, VP-16, LAK cells and antibodies.
Gulati SC; Shimazaki C; Lemoli RM; Atzpodien J; Clarkson BD
Eur J Haematol Suppl; 1989; 51():164-72. PubMed ID: 2627987
[TBL] [Abstract][Full Text] [Related]
33. Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood sources.
Léonard BM; Hétu F; Busque L; Gyger M; Bélanger R; Perreault C; Roy DC
Blood; 1998 Jan; 91(1):331-9. PubMed ID: 9414302
[TBL] [Abstract][Full Text] [Related]
34. Ex vivo expansion of CD34+ peripheral blood progenitor cells: implications for the expansion of contaminating epithelial tumor cells.
Vogel W; Behringer D; Scheding S; Kanz L; Brugger W
Blood; 1996 Oct; 88(7):2707-13. PubMed ID: 8839866
[TBL] [Abstract][Full Text] [Related]
35. Effective purging of autologous hematopoietic stem cells using anti-B-cell monoclonal antibody-coated high-density microparticles prior to high-dose therapy for patients with non-Hodgkin's lymphoma.
Webb IJ; Friedberg nW; Gribben JG; Fisher DC; Spitzer T; Neuberg D; Jallow H; Kim H; Houde H; Monroy R; Schmittling R; Freedman AS
Biol Blood Marrow Transplant; 2002; 8(8):429-34. PubMed ID: 12234168
[TBL] [Abstract][Full Text] [Related]
36. Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging.
Bergan R; Hakim F; Schwartz GN; Kyle E; Cepada R; Szabo JM; Fowler D; Gress R; Neckers L
Blood; 1996 Jul; 88(2):731-41. PubMed ID: 8695822
[TBL] [Abstract][Full Text] [Related]
37. Eradication of multiple myeloma and breast cancer cells by TH9402-mediated photodynamic therapy: implication for clinical ex vivo purging of autologous stem cell transplants.
Brasseur N; Ménard I; Forget A; el Jastimi R; Hamel R; Molfino NA; van Lier JE
Photochem Photobiol; 2000 Dec; 72(6):780-7. PubMed ID: 11140266
[TBL] [Abstract][Full Text] [Related]
38. Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study.
Belhadj K; Delfau-Larue MH; Elgnaoui T; Beaujean F; Beaumont JL; Pautas C; Gaillard I; Kirova Y; Allain A; Gaulard P; Farcet JP; Reyes F; Haioun C
Ann Oncol; 2004 Mar; 15(3):504-10. PubMed ID: 14998857
[TBL] [Abstract][Full Text] [Related]
39. CD34+ subset and tumor cell quantitation by flow cytometry--step toward quality assessment of autografts in B cell malignancies.
Johnsen HE; Rasmussen T; Knudsen LM
Vox Sang; 1998; 74 Suppl 2():477-82. PubMed ID: 9704485
[TBL] [Abstract][Full Text] [Related]
40. Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution.
Michallet M; Philip T; Philip I; Godinot H; Sebban C; Salles G; Thiebaut A; Biron P; Lopez F; Mazars P; Roubi N; Leemhuis T; Hanania E; Reading C; Fine G; Atkinson K; Juttner C; Coiffier B; Fière D; Archimbaud E
Exp Hematol; 2000 Jul; 28(7):858-70. PubMed ID: 10907648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
